We're #14 in the US and #17 in Europe...the biggest of the Danaher diagnostic companies. We sell robotics, AST, and viral immunoassays.
We're #18 in the US and #31 in Europe. We're the American swab and media team.
We're #5 in Europe but only #15 in the US, because the FDA was slow to approve our Healgen rapid antigen tests.
We're #7 in the US and #12 in Europe. We sold a lot of rapid antigen tests in 2020, then a lot less in 2021.
We're #3 in the US and #10 in Europe. Who says you can't herd cats? We've trained our felines to run small covid panels, STI tests, and viral loads.
We're #1 in Europe and #5 in the US. If the FDA hadn't been so slow to approve our SD fast antigen kits, we'd be #1 on both sides of the Atlantic.
We're #9 in both Europe and the US. We make our Covid money four ways: open-system PCR, serology, robotics, and lab services
We were #24 in the US and #28 in Europe last year, but we're rising fast. We're the apex predator of NGS markets; our patents are expiring soon, so no rest for the weary.
We're #8 in Europe and #6 in the US. We're hard to beat in AST and syndromic panels.
We're #14 in Europe and #16 in the US. We took our cats out of the blood bank and into Iberia's Covid labs.
We're #8 in the US and #21 in Europe. Our revenues were $1.7b in 2020, and about the same last year. Then we took in $1b in 1Q22.
We're #19 in both the US and Europe. We're the Italian swab & media team.
We were #23 in Europe last year, but we don't sell much in the US. We make the Siemens rapid antigen tests.
We're #17 in the US and #18 in Europe. We're the incumbent power of ddPCR instrumentation and viral QC.
We're #13 in the US and #24 in Europe. We just got acquired cheap - barely three times revenues